study provided clinical evidence that loss of Bad is an independent and powerful predictor of adverse prognosis in non-small cell lung cancer

Inhibition of mTOR by rapamycin stimulates Bad phosphorylation at S112 and S136 through activation of ERK1/2 and Akt, which decreased sensitivity of lung cancer cells to mTOR inhibition.

A Novel Naphthalimide Compound Restores p53 Function in Non-small Cell lung cancer by Reorganizing the Bak.Bcl-xl Complex and Triggering Transcriptional Regulation.

we can conclude that patients with small cell lung carcinoma represent downregulation of Bad and the latter could be served as a useful biomarker for the outcomes of SCLC.

EGFR-independent EGFR-mutant lung adenocarcinoma cells depend on Bcl-xL and MCL1 for survival.